Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2023 | The role of immunotherapy in cholangiocarcinoma

Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses the role of immunotherapy in cholangiocarcinoma. The randomized Phase III TOPAZ-1 (NCT03875235) study investigating first-line gemcitabine plus cisplatin with or without durvalumab patients with advanced biliary tract cancer demonstrated an improvement in overall-survival (OS), progression-free survival (PFS) and response rate with the addition of durvalumab. Although there was a median improvement in PFS of under 2 months, a subpopulation of patients were shown to significantly benefit from the addition of immunotherapy. The Phase III KEYNOTE-966 (NCT04003636) study investigating the addition of pembrolizumab to gemcitabine and cisplatin demonstrated an improvement in OS in the first-line setting. Dr Kim highlights the importance of biomarker analysis to uncover which patients benefit from immunotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.